Shares of OvaScience Inc. jumped by nearly 17% at one point on Tuesday as investors were encouraged by promising preliminary findings for a treatment that energizes the eggs of infertile women during in-vitro fertilization. OvaScience's treatment, known as Augment, uses the mitochondria from immature egg cells inside the protective ovarian lining to improve the health of weaker eggs as they are fertilized with sperm. The latest results, however, were not due to be presented until later in the week at a conference in San Francisco. In recent action, shares of OvaScience were up nearly 11% to $52.78.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below